Designating ephedrine and pseudoephedrine products as schedule V controlled substances; restricting the sale of methamphetamine precursor drugs and imposing criminal penalties for violation, exceptions; requiring the reporting of suspicious transactions to owners, supervisors or managers of business establishments offering for sale methamphetamine precursor drugs; specifying immunity from civil liabiltiy; specifying certain certification and publication duties of the board of pharmacy
(ra)